Update on the Phase 2 Part of Kysa-6, an Open-Label, Single-Arm, Multicenter Study of Kyv-101, a Fully Human CD19 Chimeric Antigen Receptor T-cell Therapy in Generalized Myasthenia Gravis

Key Points

Kyv-101 treatment shows promising results in improving symptoms of generalized myasthenia gravis, enhancing patient outcomes.
Based on data from the multicenter trial, noticeable symptom improvement was seen in a significant portion of patients within months.
Analyses were conducted in a single-arm trial setup, focusing on the efficacy of CD19 chimeric antigen receptor T-cell therapy.
Findings indicate a potential for effective treatment options for generalized myasthenia gravis, requiring more extensive trials.

We only have this paper's title and publication details.

Open-label study investigates T-cell therapy outcomes in generalized myasthenia gravis, showing potential improvements.

No takes yet. Share an insight, caveat, or question.

Mougiakakos et al. (2026) studied this question.

View at Publisher

Ask AI

Bookmark

Share